The estimated Net Worth of Lars Ekman is at least $1.31 Milione dollars as of 3 January 2023. Lars Ekman owns over 15,834 units of Ultragenyx Pharmaceutical stock worth over $905,617 and over the last 12 years he sold RARE stock worth over $4,542. In addition, he makes $399,890 as Independent Director at Ultragenyx Pharmaceutical.
Lars has made over 10 trades of the Ultragenyx Pharmaceutical stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 15,834 units of RARE stock worth $101,496 on 3 January 2023.
The largest trade he's ever made was exercising 91,016 units of Ultragenyx Pharmaceutical stock on 3 September 2019 worth over $320,376. On average, Lars trades about 5,639 units every 61 days since 2013. As of 3 January 2023 he still owns at least 16,077 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Lars Ekman stock trades at the bottom of the page.
Dr. Lars G. Ekman M.D., Ph.D. serves as Independent Director of the Company. He has more than 30 years of experience in the pharmaceutical industry and is currently an executive partner at Sofinnova, a venture capital firm, where Dr. Ekman has served as executive partner since March 2008. He currently serves as Chairman of the Board of Amarin Corporation plc, a public biopharmaceutical company, Chairman of the Board of Sophiris Bio, Inc., a public biopharmaceutical company, and Chairman of the Board of Prothena Corporation plc, a public neuroscience company. Dr. Ekman previously served on the boards of Spark Therapeutics, Inc. from 2015 until December 2019, Elan Corporation plc from 2007 through 2013, InterMune Inc. from 2006 through 2013, and Ocera Therapeutics, Inc. from 2009 through 2015. From October 2008 to 2011, he served as Co-Founder and Chief Executive Officer of Cebix Inc., a C-peptide replacement therapy company. He was Executive Vice President and President of Global Research and Development at Elan Corporation plc, from January 2001 to December 2007. Prior to joining Elan, he was Executive Vice President, Research and Development at Schwarz Pharma AG from February 1997 to December 2000, and prior to that was employed in a variety of senior scientific and clinical functions at Pharmacia, now Pfizer Inc.
As the Independent Director of Ultragenyx Pharmaceutical, the total compensation of Lars Ekman at Ultragenyx Pharmaceutical is $399,890. There are 15 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
Lars Ekman is 70, he's been the Independent Director of Ultragenyx Pharmaceutical since 2016. There are 1 older and 24 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
Lars's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr e Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: